Ophthotech Corp.
Funding rounds
3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2018 | $11 M | Issued in a merger or acquisition | $10 to $50 million | equity | SEC | |
| May 2013 | $17 M | No. 3 | $10 to $50 million | equity | SEC | |
| Dec 2009 | $15 M | No. 2 | $10 to $50 million | equity | SEC | |
| Oct 2009 | $3 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Ophthotech Corp. chose not to state its revenue in its newest notice of a funding round (Nov 2018).
SEC Form D · Nov 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2018
That is all the official record says: Ophthotech Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: its website does not allow automated readers.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Clarus Lifesciences II, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Clarus Ventures II GP, L.P. | Venture capital | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Clarus Ventures II, LLC | Venture capital | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| HBM Healthcare Investments (Cayman) Ltd. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| SV Life Sciences Fund IV (GP), L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| SV Life Sciences Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| SV Life Sciences Fund IV Strategic Partners, L. P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Svlsf IV, LLC | Other | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 7 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Guyer | Executive officer | Nov 2018 |
| David Pritchett Carroll | Executive officer | Nov 2018 |
| Glenn Sblendorio | Executive officer | Nov 2018 |
| Keith Pritchett Westby | Executive officer | Nov 2018 |
| Bruce C. Peacock | Executive officer | Jun 2013 |
| David C. Guyer | Executive officer | Jun 2013 |
| Evelyn C. Harrison | Executive officer | Jun 2013 |
| Samir C. Patel | Executive officer | Jun 2013 |
| Thomas C. Biancardi | Executive officer | Dec 2009 |
| Axel Bolte | Director | Nov 2018 |
| David Guyer | Director | Nov 2018 |
| David Pritchett Redlick | Director | Nov 2018 |
| Glenn Sblendorio | Director | Nov 2018 |
| Jane Pritchett Henderson | Director | Nov 2018 |
| Michael Ross | Director | Nov 2018 |
| Thomas Dyrberg | Director | Nov 2018 |
| Axel C. Bolte | Director | Jun 2013 |
| David C. Guyer | Director | Jun 2013 |
| Michael C. Ross | Director | Jun 2013 |
| Nicholas C. Galakatos | Director | Jun 2013 |
| Samir C. Patel | Director | Jun 2013 |
| Thomas C. Dyrberg | Director | Jun 2013 |
| Alex C. Bolte | Director | Dec 2009 |
| Henry C. Simon | Director | Dec 2009 |
About
Company in New York, United States.